Teva's ecopipam secures FDA priority review for pediatric Tourette syndrome, potentially bringing the first new therapy in over a decade.

Precigen's Papzimeos drives rapid revenue growth, while market exclusivity, global expansion and its pipeline add long-term potential.

Ultragenyx stock rises as Genglycos wins FDA's accelerated approval as the first treatment targeting the underlying cause of GSDIa, boosting its rare-disease portfolio.

A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.

Amylyx surges after avexitide cuts hypoglycemic events 55% in phase III LUCIDITY study, paving the way for an FDA filing by end-2026 in PBH.

NVCT's 97% three-month gain reflects optimism around its expanding pipeline, with NXP100 and NXP200 offering new value drivers.

CareDx, Healthcare Services Group, Forum Energy Technologies, Amneal Pharmaceuticals and Caterpillar emerge as high-efficiency stocks poised for stronger returns.

argenx's shares jump 16% as Vyvgart Hytrulo delivered positive phase III ALKIVIA data, supporting its potential label expansion in autoimmune myositis.

EyePoint's Duravyu misses the phase III wet AMD study's primary goal, sending shares down 67%, but shows lower treatment burden and durable disease control.

United Therapeutics completes enrollment in its phase III study evaluating Tyvaso for an additional indication, PPF, with top-line results expected in the second half of 2027.